- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03249155
Action Observation Plus Sonification Therapeutic Protocol (AOFREEPD)
Action Observation Plus Sonification. A Novel Therapeutic Protocol for Parkinson's Patient With Freezing of Gait
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
FoG is a disabling and distressing symptom strictly associated to falls. The little or no pharmacological responsiveness of FoG has led to an increasing interest in rehabilitation interventions aimed at functional recovery and autonomy. Currently, standard protocols employed for rehabilitation are based on the use of external (visual and auditory) sensory cues. However, cued strategies generate an important dependence on the environment. Teaching motor strategies without cues (i.e. action observation - AO) can be an alternative/innovative approach to rehabilitation, that matters most on appropriate allocation of attention and lightening cognitive load. One way to increase the effectiveness of AO, is the use of a multisensory learning mode (visual and auditory) to facilitate the recovery of motor gestures thanks to enhanced perceptual processes, which is known to be reduced in PD with FoG. Sonification could be an important method to enhance therapeutical effects in action observation rehabilitation process. Sonification of movements amplifies the activity of the human action observation system including subcortical structures of the motor loop.
Methods. We compared the effects of two different therapeutic protocols. The experimental protocol was based on action observation plus sonification; patients of the experimental group re-learned 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip was composed by images and sounds of the gestures. The sounds of gestures were obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example). The same 8 motor gestures were re-learned in the standard protocol, with a common sensory stimulation method (active comparator group). We evaluated all patients of the two groups with functional and clinical scales before, immediately after, at 1 month, and 3 months after each treatment.The duration of each protocol will be about 2 months, 15 sessions, 2 times a week.
Data Safety Monitoring Plan. The patients' assignment to the two groups was as follow: a list of 20 patients (10 patients for each group) was created and the order fully randomized. The list was filled with the patients following the order of arrival from the Neurology Clinic (Cattinara Hospital, Trieste). All the evaluations (neuropsychological, neurological, and physiotherapy) are blind respect to the patient's group assignment. The person in charge to make assignment patient-treatment will not be the PI.
Sample size calculation. The dependent variable (the primary outcome measure) is the score of the N-FOG Questionnaire. Sample size has been calculated considering a repeated measures mixed ANOVA of the primary outcome measure, with the software G*Power 3. The result gives a sample size of 20 patients: 10 for each group (experimental and active comparator group). The sizing of the sample is justified by similar protocols evaluations that with an identical sample size (n = 10 per group) found statistically significant results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Parkinson's Disease Diagnosis (UK Brain Bank)
- H&R stage < or = to 3;
- score of 1 on the 1st question of the NFOG-Q;
- no comorbidities that would preclude physiotherapy treatment;
- Back Depression Scale score < or = to 16;
- stabilized pharmacological therapy
Exclusion Criteria:
- dementia: MMSE > or = to 24
- past neuropathies, ictus or myelopathies
- orthopaedic comorbidity that may impede walking
- presence of DBS
- severe psychiatric pathology
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AO - plus sonification
patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
|
patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
Each video-clip is composed by images and sounds of the gestures.
The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
|
Active Comparator: CUE - visual and auditory
patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
|
patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(Changes in) New Freezing of Gait Questionnaire - NFOG-Q
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Questionnaire
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(Changes in) Unified Parkinson Disease Rating Scale - part 2, 3
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Scale
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
(Changes in) BERG Balance Scale
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Scale
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
(Changes in) MPAS - Modified Parkinson Assessment Scale
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Scale
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
(Changes in) TUG - Time Up and Go
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Test
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
(Changes in) 6MWT - Six Minutes Walking Test
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Clinical Administered Test
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
(Changes in) PDQ-39 - Parkinson Disease Quality of Life Questionnaire
Time Frame: Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
39 Items Self Administered Questionnaire
|
Before treatment, 2-months (end of treatment), 3-months, and 5-months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paolo Bernardis, PhD, University of Trieste
Publications and helpful links
General Publications
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.
- Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 2011 Aug;10(8):734-44. doi: 10.1016/S1474-4422(11)70143-0.
- Pelosin E, Avanzino L, Bove M, Stramesi P, Nieuwboer A, Abbruzzese G. Action observation improves freezing of gait in patients with Parkinson's disease. Neurorehabil Neural Repair. 2010 Oct;24(8):746-52. doi: 10.1177/1545968310368685. Epub 2010 May 7.
- Patla AE, Vickers JN. Where and when do we look as we approach and step over an obstacle in the travel path? Neuroreport. 1997 Dec 1;8(17):3661-5. doi: 10.1097/00001756-199712010-00002.
- Stefan K, Cohen LG, Duque J, Mazzocchio R, Celnik P, Sawaki L, Ungerleider L, Classen J. Formation of a motor memory by action observation. J Neurosci. 2005 Oct 12;25(41):9339-46. doi: 10.1523/JNEUROSCI.2282-05.2005.
- Vinken PM, Kroger D, Fehse U, Schmitz G, Brock H, Effenberg AO. Auditory coding of human movement kinematics. Multisens Res. 2013;26(6):533-52. doi: 10.1163/22134808-00002435. Erratum In: Multisens Res. 2014;27(3-4):263-4.
- Schmitz G, Mohammadi B, Hammer A, Heldmann M, Samii A, Munte TF, Effenberg AO. Observation of sonified movements engages a basal ganglia frontocortical network. BMC Neurosci. 2013 Mar 14;14:32. doi: 10.1186/1471-2202-14-32.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTrieste
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on AO - plus sonification
-
China Medical University HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Istituti Clinici Scientifici Maugeri SpARecruitingStroke | Multiple Sclerosis | Parkinson DiseaseItaly
-
Hospital Cruz Roja MexicanaUnknown
-
ActiveO Inc.CompletedDisk, HerniatedCanada
-
TherOxCompletedMyocardial InfarctionUnited States
-
A2A Pharmaceuticals Inc.RecruitingTriple Negative Breast Cancer | Endometrial Cancer | High Grade Serous Ovarian CancerUnited States
-
Arch OncologyCompletedMultiple MyelomaUnited States
-
Temple UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingObesity | Overweight | Pregnancy RelatedUnited States
-
Duke UniversityTerminatedDiabetic Retinopathy | Diabetic Macular EdemaUnited States
-
AOBiome LLCCompletedAtopic Dermatitis EczemaUnited States